Interactions of Alginate-Deferoxamine Conjugates With Blood Components and Their Antioxidation in the Hemoglobin Oxidation Model
While deferoxamine (DFO) has long been used as an FDA-approved iron chelator, its proangiogenesis ability attracts increasing number of research interests. To address its drawbacks such as short plasma half-life and toxicity, polymeric conjugated strategy has been proposed and shown superiority. Owi...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-02-01
|
Series: | Frontiers in Bioengineering and Biotechnology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fbioe.2020.00053/full |
id |
doaj-562670902a0a491eb979dd26ea2b02da |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tong Sun Tong Sun Xi Guo Xi Guo Rui Zhong Chengwei Wang Chengwei Wang Hao Liu Hao Liu Hao Li Lu Ma Junwen Guan Chao You Chao You Chao You Meng Tian Meng Tian Meng Tian |
spellingShingle |
Tong Sun Tong Sun Xi Guo Xi Guo Rui Zhong Chengwei Wang Chengwei Wang Hao Liu Hao Liu Hao Li Lu Ma Junwen Guan Chao You Chao You Chao You Meng Tian Meng Tian Meng Tian Interactions of Alginate-Deferoxamine Conjugates With Blood Components and Their Antioxidation in the Hemoglobin Oxidation Model Frontiers in Bioengineering and Biotechnology deferoxamine blood components antioxidation alginate conjugates |
author_facet |
Tong Sun Tong Sun Xi Guo Xi Guo Rui Zhong Chengwei Wang Chengwei Wang Hao Liu Hao Liu Hao Li Lu Ma Junwen Guan Chao You Chao You Chao You Meng Tian Meng Tian Meng Tian |
author_sort |
Tong Sun |
title |
Interactions of Alginate-Deferoxamine Conjugates With Blood Components and Their Antioxidation in the Hemoglobin Oxidation Model |
title_short |
Interactions of Alginate-Deferoxamine Conjugates With Blood Components and Their Antioxidation in the Hemoglobin Oxidation Model |
title_full |
Interactions of Alginate-Deferoxamine Conjugates With Blood Components and Their Antioxidation in the Hemoglobin Oxidation Model |
title_fullStr |
Interactions of Alginate-Deferoxamine Conjugates With Blood Components and Their Antioxidation in the Hemoglobin Oxidation Model |
title_full_unstemmed |
Interactions of Alginate-Deferoxamine Conjugates With Blood Components and Their Antioxidation in the Hemoglobin Oxidation Model |
title_sort |
interactions of alginate-deferoxamine conjugates with blood components and their antioxidation in the hemoglobin oxidation model |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Bioengineering and Biotechnology |
issn |
2296-4185 |
publishDate |
2020-02-01 |
description |
While deferoxamine (DFO) has long been used as an FDA-approved iron chelator, its proangiogenesis ability attracts increasing number of research interests. To address its drawbacks such as short plasma half-life and toxicity, polymeric conjugated strategy has been proposed and shown superiority. Owing to intravenous injection and application in blood-related conditions, however, the blood interactions and antioxidation of the DFO-conjugates and the mechanisms underlying these outcomes remain to be elucidated. In this regard, incubating with three different molecular-weight (MW) alginate-DFO conjugates (ADs) red blood cells (RBCs), coagulation system, complement and platelet were investigated. To prove the antioxidant activity of ADs, we used hemoglobin oxidation model in vitro. ADs did not cause RBCs hemolysis while reversible aggregation and normal deformability ability were observed. However, the coagulation time, particularly APTT and TT, were significantly prolonged in a dose-dependent manner, and fibrinogen was dramatically decreased, suggesting ADs could dominantly inhibit the intrinsic pathways in the process of coagulation. The dose-dependent anticoagulation might be related with the functional groups along the alginate chains. The complements, C3a and C5a, were activated by ADs in a dose-dependent manner through alternative pathway. For platelet, ADs slightly suppressed the activation and aggregation at low concentration. Based on above results, the cross-talking among coagulation, complement and platelet induced by ADs was proposed. The antioxidation of ADs through iron chelation was proved and the antioxidant activity was shown in a MW-dependent manner. |
topic |
deferoxamine blood components antioxidation alginate conjugates |
url |
https://www.frontiersin.org/article/10.3389/fbioe.2020.00053/full |
work_keys_str_mv |
AT tongsun interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel AT tongsun interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel AT xiguo interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel AT xiguo interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel AT ruizhong interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel AT chengweiwang interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel AT chengweiwang interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel AT haoliu interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel AT haoliu interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel AT haoli interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel AT luma interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel AT junwenguan interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel AT chaoyou interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel AT chaoyou interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel AT chaoyou interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel AT mengtian interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel AT mengtian interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel AT mengtian interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel |
_version_ |
1725302904029446144 |
spelling |
doaj-562670902a0a491eb979dd26ea2b02da2020-11-25T00:37:01ZengFrontiers Media S.A.Frontiers in Bioengineering and Biotechnology2296-41852020-02-01810.3389/fbioe.2020.00053520676Interactions of Alginate-Deferoxamine Conjugates With Blood Components and Their Antioxidation in the Hemoglobin Oxidation ModelTong Sun0Tong Sun1Xi Guo2Xi Guo3Rui Zhong4Chengwei Wang5Chengwei Wang6Hao Liu7Hao Liu8Hao Li9Lu Ma10Junwen Guan11Chao You12Chao You13Chao You14Meng Tian15Meng Tian16Meng Tian17Neurosurgery Research Laboratory, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, ChinaNeurosurgery Research Laboratory, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, ChinaInstitute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, ChinaNeurosurgery Research Laboratory, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, ChinaNeurosurgery Research Laboratory, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, ChinaNeurosurgery Research Laboratory, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, ChinaWest China Brain Research Centre, West China Hospital, Sichuan University, Chengdu, ChinaNeurosurgery Research Laboratory, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, ChinaWest China Brain Research Centre, West China Hospital, Sichuan University, Chengdu, ChinaWhile deferoxamine (DFO) has long been used as an FDA-approved iron chelator, its proangiogenesis ability attracts increasing number of research interests. To address its drawbacks such as short plasma half-life and toxicity, polymeric conjugated strategy has been proposed and shown superiority. Owing to intravenous injection and application in blood-related conditions, however, the blood interactions and antioxidation of the DFO-conjugates and the mechanisms underlying these outcomes remain to be elucidated. In this regard, incubating with three different molecular-weight (MW) alginate-DFO conjugates (ADs) red blood cells (RBCs), coagulation system, complement and platelet were investigated. To prove the antioxidant activity of ADs, we used hemoglobin oxidation model in vitro. ADs did not cause RBCs hemolysis while reversible aggregation and normal deformability ability were observed. However, the coagulation time, particularly APTT and TT, were significantly prolonged in a dose-dependent manner, and fibrinogen was dramatically decreased, suggesting ADs could dominantly inhibit the intrinsic pathways in the process of coagulation. The dose-dependent anticoagulation might be related with the functional groups along the alginate chains. The complements, C3a and C5a, were activated by ADs in a dose-dependent manner through alternative pathway. For platelet, ADs slightly suppressed the activation and aggregation at low concentration. Based on above results, the cross-talking among coagulation, complement and platelet induced by ADs was proposed. The antioxidation of ADs through iron chelation was proved and the antioxidant activity was shown in a MW-dependent manner.https://www.frontiersin.org/article/10.3389/fbioe.2020.00053/fulldeferoxamineblood componentsantioxidationalginateconjugates |